Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CNTX-6970 in healthy subjects
NCT03787004Phase 1Completed
- Sponsor
- Centrexion Therapeutics
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CNTX-6970 in chronic pain and nociceptive pain (4 arms), sponsored by Centrexion Therapeutics. Primary endpoints: CNTX-6970 Pharmacokinetics - fasted state or high-fat standardized meal, CNTX-6970 Pharmacokinetics - AUC0-t and 4 more. Started Aug 2017; status: completed.
02
Drugs
CNTX-6970
03
Conditions
chronic painnociceptive pain
Beyond the preview
Go deeper on NCT03787004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787004.